Palavras-chave
Sertralina
Candidíase vulvovaginal
Agente antifúngico
Administração intravaginal
Como Citar
Resumo
No contexto da alta prevalência de candidíase vulvovaginal (CVV) e da crescente resistência de espécies de Candida spp. aos tratamentos convencionais, o reposicionamento de fármacos surge como uma estratégia importante para estabelecer novos usos terapêuticos de medicamentos já aprovados clinicamente para outras indicações. Experimentos anteriores demonstraram a atividade antifúngica in vitro da sertralina, fármaco da classe dos Inibidores Seletivos da Recaptação de Serotonina (ISRS), e determinaram sua concentração inibitória mínima (CIM), constatando sua capacidade de atuar sobre fatores de virulência de alguns fungos, como leveduras do gênero Candida. No presente estudo, foi avaliado o efeito antifúngico da sertralina in vivo com o objetivo de contribuir para o desenvolvimento de uma formulação de administração vaginal contendo o fármaco para o tratamento de CVV experimental. A atividade antifúngica da sertralina em diferentes concentrações, em solução e em emulgel, foi examinada em um modelo de rata imunossuprimida e dependente de estrogênio, no qual os animais foram infectados intravaginalmente com C. albicans. Os resultados demonstraram que a sertralina, quando administrada por meio de uma matriz farmacêutica adequada ao ambiente vaginal, apresenta eficácia significativa, atingindo a cura da infecção com apenas 3 dias de tratamento. A partir desses achados, é possível afirmar que a sertralina é promissora para o reposicionamento de fármacos no tratamento da CVV.
Referências
Miró MS, Rodríguez E, Vigezzi C, Icely PA, Gonzaga de Freitas Araújo M, Riera FO, et al. Vulvovaginal candidiasis: An old disease with new challenges. Rev Iberoam Micol [Internet]. 2017;34(2):65–71. Available from: http://dx.doi.org/10.1016/j.riam.2016.11.006
Chew SY, Than LTL. Vulvovaginal candidosis: Contemporary challenges and the future of prophylactic and therapeutic approaches. Mycoses. 2016;59(5):262–73.
Sanguinetti M, Posteraro B, Lass-Flörl C. Antifungal drug resistance among Candida species: Mechanisms and clinical impact. Mycoses. 2015;58(S2):2–13.
Costa Silva RA, da Silva CR, de Andrade Neto JB, da Silva AR, Campos RS, Sampaio LS, et al. In vitro anti-Candida activity of selective serotonin reuptake inhibitors against fluconazole-resistant strains and their activity against biofilm-forming isolates. Microb Pathog. 2017;107:341–8.
Wiederhold NP. Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist. 2017;10:249–59.
Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida Species. Front Microbiol. 2017;7(JAN):1–12.
Oliveira AS, Gaspar CA, Palmeira-de-Oliveira R, Martinez-de-Oliveira J, Palmeira-de-Oliveira A. Anti-Candida activity of fluoxetine alone and combined with fluconazole: A synergistic action against fluconazole-resistant strains. Antimicrob Agents Chemother. 2014;58(7):4224–6.
Lass-Flörl C, Ledochowski M, Fuchs D, Speth C, Kacani L, Dierich MP, et al. Interaction of sertraline with Candida species selectively attenuates fungal virulence in vitro. FEMS Immunol Med Microbiol. 2003;35(1):11–5.
Lass‐Flörl C, Dierich MP, Fuchs D, Semenitz E, Ledochowski M. Antifungal Activity against Candida Species of the Selective Serotonin‐Reuptake Inhibitor, Sertraline . Clinical Infectious Diseases. 2001;33(12):e135–6.
Ashburn TT, Thor KB. Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–83.
Abrutyn E. New uses for old drugs. Infect Dis Clin North Am. 1989;3(3):653–64.
Chiang AP, Butte AJ. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clin Pharmacol Ther [Internet]. 2009;86(5):507–10. Available from: http://dx.doi.org/10.1038/clpt.2009.103
Kaitin KI. Deconstructing the drug development process: The new face of innovation. Clin Pharmacol Ther. 2010;87(3):356–61.
Naglik JR, Fidel PL, Odds FC. Animal models of mucosal Candida infection. FEMS Microbiol Lett. 2008;283(2):129–39.
(ATCC) ATCC. Candida albicans drug resistance panel (CaDR Panel). American Type Culture Collection [Internet]. 2008; Available from: https://www.atcc.org/products/all/10231.aspx#documentation
Oliveira AS, Martinez-De-Oliveira J, Palmeira-De-Oliveira R, Palmeira-De-Oliveira A. Medical Journal of Obstetrics and Gynecology Antifungal Activity of Antidepressant Sertraline against Candida Species In vitro: A Potential Beneficial Association with Fluconazole. Med J Obstet Gynecol [Internet]. 2017;5(1):1–5. Available from: https://www.jscimedcentral.com/Obstetrics/obstetrics-5-1095.pdf
Samanta A, Chattopadhyay D, Sinha C, Dulal Jana A, Ghosh S, Mandal A, et al. Evaluation of In Vivo and In Vitro Antimicrobial Activities of a Selective Serotonin Reuptake Inhibitor Sertraline Hydrochloride. Antiinfect Agents. 2014;10(2):95–104.
Zhai B, Wu C, Wang L, Sachs MS, Lin X. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother. 2012;56(7):3758–66.
de Oliveira Neto AS, Souza ILA, Amorim MES, de Freitas Souza T, Rocha VN, do Couto RO, et al. Antifungal efficacy of atorvastatin-containing emulgel in the treatment of oral and vulvovaginal candidiasis. Med Mycol. 2020;1–10.
Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42(6):905–27.
Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf [Internet]. 2017;16(2):149–65. Available from: http://dx.doi.org/10.1080/14740338.2017.1270264
Villalba MA. Reposicionamento de fármacos para tratamento de doenças infecciosas bacterianas. 2015;31. Available from: http://www.bibliotecadigital.ufmg.br/dspace/handle/1843/BUBD-A4VGJT
Young TJ, Oliver GP, Pryde D, Perros M, Parkinson T. Antifungal activity of selective serotonin reuptake inhibitors attributed to non-specific cytotoxicity [5]. Journal of Antimicrobial Chemotherapy. 2003;51(4):1045–7.
Paul S, Mortimer RB, Mitchell M. Sertraline demonstrates fungicidal activity in vitro for Coccidioides immitis. Mycology [Internet]. 2016;7(3):99–101. Available from: http://dx.doi.org/10.1080/21501203.2016.1204368
Lass-Florl C. Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. Journal of Antimicrobial Chemotherapy. 2001;48(6):775–9.
Carrara MA, Donatti L, Damke E, Svidizinski TIE, Consolaro MEL, Batista MR. A new model of vaginal infection by Candida albicans in rats. Mycopathologia. 2010;170(5):331–8.
de Freitas Araújo MG, Pacífico M, Vilegas W, dos Santos LC, Icely PA, Miró MS, et al. Evaluation of Syngonanthus nitens (Bong.) Ruhl. extract as antifungal and in treatment of vulvovaginal candidiasis. Med Mycol. 2013;51(7):673–82.
Cassone A, Sobel JD. Experimental models of vaginal candidiasis and their relevance to human candidiasis. Infect Immun. 2016;84(5):1255–61.
Johal HS, Garg T, Rath G, Goyal AK. Advanced topical drug delivery system for the management of vaginal candidiasis. Drug Deliv. 2016;23(2):550–63.
Rajaram DM, Laxman SD. Buccal mucoadhesive films: A review. Systematic Reviews in Pharmacy. 2017;8(1):31–8.
Kataria K, Sharma A, Garg T, Goyal AK, Rath G. Novel Technology to Improve Drug Loading in Polymeric Nanofibers. 2014.
Araujo VHS, Duarte JL, Carvalho GC, Silvestre ALP, Fonseca-Santos B, Marena GD, et al. Nanosystems against candidiasis: a review of studies performed over the last two decades. Vol. 46, Critical Reviews in Microbiology. Taylor and Francis Ltd.; 2020. p. 508–47.
Ajazuddin, Alexander A, Khichariya A, Gupta S, Patel RJ, Giri TK, et al. Recent expansions in an emergent novel drug delivery technology: Emulgel. Journal of Controlled Release [Internet]. 2013;171(2):122–32. Available from: http://dx.doi.org/10.1016/j.jconrel.2013.06.030
Valenta C. The use of mucoadhesive polymers in vaginal delivery. Vol. 57, Advanced Drug Delivery Reviews. 2005. p. 1692–712.
Jalil A, Asim MH, Le NMN, Laffleur F, Matuszczak B, Tribus M, et al. S-protected gellan gum: Decisive approach towards mucoadhesive antimicrobial vaginal films. Int J Biol Macromol. 2019 Jun 1;130:148–57.
Calvo NL, Svetaz LA, Alvarez VA, Quiroga AD, Lamas MC, Leonardi D. Chitosan-hydroxypropyl methylcellulose tioconazole films: A promising alternative dosage form for the treatment of vaginal candidiasis. Int J Pharm. 2019 Feb 10;556:181–91.
Mesquita L, Galante J, Nunes R, Sarmento B, Neves J das. Pharmaceutical vehicles for vaginal and rectal administration of anti-hivmicrobicide nanosystems. Vol. 11, Pharmaceutics. MDPI AG; 2019.
Chindamo G, Sapino S, Peira E, Chirio D, Gallarate M. Recent advances in nanosystems and strategies for vaginal delivery of antimicrobials. Nanomaterials. 2021 Feb 1;11(2):1–29.
Osmałek T, Froelich A, Jadach B, Tatarek A, Gadzinski P, Falana A, et al. Recent advances in polymer-based vaginal drug delivery systems. Pharmaceutics. 2021 Jun 1;13(6).
Sun X, Qiu H, Jin Y. Highly efficient treatment of aerobic vaginitis with simple acidic buffered gels: The importance of pH and buffers on the microenvironment of vaginas. Int J Pharm. 2017 Jun 15;525(1):175–82.
Wang X, Liu S, Guan Y, Ding J, Ma C, Xie Z. Vaginal drug delivery approaches for localized management of cervical cancer. Vol. 174, Advanced Drug Delivery Reviews. Elsevier B.V.; 2021. p. 114–26.
dos Santos AM, Carvalho SG, Araujo VHS, Carvalho GC, Gremião MPD, Chorilli M. Recent advances in hydrogels as strategy for drug delivery intended to vaginal infections. Vol. 590, International Journal of Pharmaceutics. Elsevier B.V.; 2020.
Notario-Pérez F, Cazorla-Luna R, Martín-Illana A, Galante J, Ruiz-Caro R, das Neves J, et al. Design, fabrication and characterisation of drug-loaded vaginal films: State-of-the-art. Vol. 327, Journal of Controlled Release. Elsevier B.V.; 2020. p. 477–99.
Thapa R, Gurung S, Parat MO, Parekh HS, Pandey P. Application of Sol–Gels for Treatment of Gynaecological Conditions—Physiological Perspectives and Emerging Concepts in Intravaginal Drug Delivery. Vol. 8, Gels. MDPI; 2022.
Sekhavat L, Tabatabaii A, Tezerjani FZ. Oral fluconazole 150mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis. J Infect Public Health. 2011 Sep;4(4):195–9.
Martens MG. Patient Preferences in the Treatment of Vaginal Candidiasis. Open J Obstet Gynecol. 2018;08(12):1147–55.
Mendling W, Shazly MA el, Zhang L. Clotrimazole for vulvovaginal candidosis: More than 45 years of clinical experience. Vol. 13, Pharmaceuticals. MDPI AG; 2020. p. 1–26.
Boyd KL, Muehlenbachs A, Rendi MH, Garcia RL, Gibson-Corley KN. Female Reproductive System. In: Comparative Anatomy and Histology [Internet]. Elsevier; 2018. p. 303–34. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780128029008000178
Andrade JT, Santos FRS, Lima WG, Sousa CDF, Oliveira LSFM, Ribeiro RIMA, et al. Design, synthesis, biological activity and structure-activity relationship studies of chalcone derivatives as potential anti-Candida agents. Journal of Antibiotics. 2018 Aug 1;71(8):702–12.
de Toledo LG, Ramos MADS, da Silva PB, Rodero CF, de Sá Gomes V, da Silva AN, et al. Improved in vitro and in vivo anti-candida albicans activity of cymbopogon nardus essential oil by its incorporation into a microemulsion system. Int J Nanomedicine. 2020;15:10481–97.
Muñoz JE, Rossi DCP, Ishida K, Spadari CC, Melhem MSC, Garcia DM, et al. Antifungal activity of the biphosphinic cyclopalladate C7a against Candida albicans yeast forms in vitro and in vivo. Front Microbiol. 2017 May 3;8(MAY).
Andrade JT, Lima WG, Sousa JF, Saldanha AA, Nívea Pereira De Sá, Morais FB, et al. Design, synthesis, and biodistribution studies of new analogues of marine alkaloids: Potent in vitro and in vivo fungicidal agents against Candida spp. Eur J Med Chem. 2021 Jan 15;210.
Lima WG, Alves-Nascimento LA, Andrade JT, Vieira L, de Azambuja Ribeiro RIM, Thomé RG, et al. Are the Statins promising antifungal agents against invasive candidiasis? Biomedicine and Pharmacotherapy. 2019 Mar 1;111:270–81.
Blanco AR, Nostro A, D’Angelo V, D’Arrigo M, Mazzone MG, Marino A. Efficacy of a fixed combination of tetracycline, chloramphenicol, and colistimethate sodium for treatment of Candida albicans keratitis. Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4292–8.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Lisandra Alves Teixeira, Marcelo Gonzaga de Freitas Araújo, Beatriz Spinelli Santos Pereira, Isabela Luana Reis Nunes, Letícia de Castro Meira Vaz, Maria Eduarda Rodrigues Ferreira, Rafaella Rangel Barbosa, João Paulo Costa Rodrigues, Rúbia Bellard e Silva, Rafael Gonçalves Teixeira-Neto, Renê Oliveira do Couto